Literature DB >> 26460138

Modulating the durability of anti-HIV gp120 antibody responses after vaccination: a comment on Wilson & Karp (2015).

Anthony L DeVico1, George K Lewis2, Robert C Gallo2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26460138      PMCID： PMC4614742          DOI： 10.1098/rstb.2015.0199

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN： 0962-8436            Impact factor:   6.237


× No keyword cloud information.
  9 in total

1.  Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.

Authors:  Isabel Leroux-Roels; Marguerite Koutsoukos; Frédéric Clement; Sophia Steyaert; Michel Janssens; Patricia Bourguignon; Kristen Cohen; Marcus Altfeld; Pierre Vandepapelière; Louise Pedneault; Lisa McNally; Geert Leroux-Roels; Gerald Voss
Journal:  Vaccine       Date:  2010-08-20       Impact factor: 3.641

Review 2.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

Review 3.  Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.

Authors:  George K Lewis; Anthony L DeVico; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-27       Impact factor: 11.205

4.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Authors:  Barton F Haynes; Peter B Gilbert; M Juliana McElrath; Susan Zolla-Pazner; Georgia D Tomaras; S Munir Alam; David T Evans; David C Montefiori; Chitraporn Karnasuta; Ruengpueng Sutthent; Hua-Xin Liao; Anthony L DeVico; George K Lewis; Constance Williams; Abraham Pinter; Youyi Fong; Holly Janes; Allan DeCamp; Yunda Huang; Mangala Rao; Erik Billings; Nicos Karasavvas; Merlin L Robb; Viseth Ngauy; Mark S de Souza; Robert Paris; Guido Ferrari; Robert T Bailer; Kelly A Soderberg; Charla Andrews; Phillip W Berman; Nicole Frahm; Stephen C De Rosa; Michael D Alpert; Nicole L Yates; Xiaoying Shen; Richard A Koup; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Nelson L Michael; Jerome H Kim
Journal:  N Engl J Med       Date:  2012-04-05       Impact factor: 91.245

5.  Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.

Authors:  Paul A Goepfert; Georgia D Tomaras; Helen Horton; David Montefiori; Guido Ferrari; Mark Deers; Gerald Voss; Marguerite Koutsoukos; Louise Pedneault; Pierre Vandepapeliere; M Juliana McElrath; Paul Spearman; Jonathan D Fuchs; Beryl A Koblin; William A Blattner; Sharon Frey; Lindsey R Baden; Clayton Harro; Thomas Evans
Journal:  Vaccine       Date:  2006-08-10       Impact factor: 3.641

6.  Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

Authors:  Merlin L Robb; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Prayura Kunasol; Chirasak Khamboonruang; Prasert Thongcharoen; Patricia Morgan; Michael Benenson; Robert M Paris; Joseph Chiu; Elizabeth Adams; Donald Francis; Sanjay Gurunathan; Jim Tartaglia; Peter Gilbert; Don Stablein; Nelson L Michael; Jerome H Kim
Journal:  Lancet Infect Dis       Date:  2012-05-30       Impact factor: 25.071

7.  Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.

Authors:  Nicole L Yates; Hua-Xin Liao; Youyi Fong; Allan deCamp; Nathan A Vandergrift; William T Williams; S Munir Alam; Guido Ferrari; Zhi-yong Yang; Kelly E Seaton; Phillip W Berman; Michael D Alpert; David T Evans; Robert J O'Connell; Donald Francis; Faruk Sinangil; Carter Lee; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Abraham Pinter; Susan Zolla-Pazner; Peter B Gilbert; Gary J Nabel; Nelson L Michael; Jerome H Kim; David C Montefiori; Barton F Haynes; Georgia D Tomaras
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

Review 8.  Can immunological principles and cross-disciplinary science illuminate the path to vaccines for HIV and other global health challenges?

Authors:  Christopher B Wilson; Christopher L Karp
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-19       Impact factor: 6.237

Review 9.  Mechanisms that determine plasma cell lifespan and the duration of humoral immunity.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Immunol Rev       Date:  2010-07       Impact factor: 12.988
  9 in total
  3 in total

1.  A reply to DeVico, Lewis & Gallo (2015).

Authors:  Christopher B Wilson; Christopher L Karp
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-11-05       Impact factor: 6.237

2.  Methods for comparing durability of immune responses between vaccine regimens in early-phase trials.

Authors:  Ted Westling; Michal Juraska; Kelly E Seaton; Georgia D Tomaras; Peter B Gilbert; Holly Janes
Journal:  Stat Methods Med Res       Date:  2019-01-09       Impact factor: 3.021

3.  HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.

Authors:  Sallie R Permar; Genevieve G Fouda; Erin P McGuire; Youyi Fong; Christopher Toote; Coleen K Cunningham; Elizabeth J McFarland; William Borkowsky; Susan Barnett; Hannah L Itell; Amit Kumar; Glenda Gray; M Julianna McElrath; Georgia D Tomaras
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.